Ibrutinib deacryloylpiperidine

Overview

Ibrutinib deacryloylpiperidine (IBT4A) is a derivative of an Ibrutinib ( HY-10997 ) intermediate and an Ibrutinib impurity. Ibrutinib deacryloylpiperidine serves as a starting material and is used in the synthesis of a modified BTK inhibitor derivative via the Mitsunobu reaction .

Application

Products | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Drug Intermediate | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-78727
• CAS No.: 330786-24-8
• Molecular Formula: C17H13N5O
• Molecular Weight: 303.32
• Purity: 99.96%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: 2.5 mg/mL (8.24 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source